RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ono Pharmaceutical Co Stock

Ono Pharmaceutical Co EBIT 2024

Ono Pharmaceutical Co EBIT

160.05 B JPY

Ticker

4528.T

ISIN

JP3197600004

WKN

859650

In 2024, Ono Pharmaceutical Co's EBIT was 160.05 B JPY, a 6.87% increase from the 149.76 B JPY EBIT recorded in the previous year.

The Ono Pharmaceutical Co EBIT history

YEAREBIT (undefined JPY)
2027e120.19
2026e111.1
2025e103.27
2024160.05
2023149.76
2022110.56
202198.49
202077.45
201963.31
201857.95
201776.1
201630.39
201514.79
201426.42
201331.92
201237.9
201135.2
201039.84
200943.47
200852.29
200752.84
200656.94
200560.05

Ono Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ono Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ono Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ono Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ono Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ono Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ono Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ono Pharmaceutical Co’s growth potential.

Ono Pharmaceutical Co Revenue, EBIT and net profit per share

DateOno Pharmaceutical Co RevenueOno Pharmaceutical Co EBITOno Pharmaceutical Co Net Income
2027e512.73 B undefined120.19 B undefined90.66 B undefined
2026e508.95 B undefined111.1 B undefined87.52 B undefined
2025e481.43 B undefined103.27 B undefined83.65 B undefined
2024502.67 B undefined160.05 B undefined127.98 B undefined
2023447.19 B undefined149.76 B undefined112.72 B undefined
2022361.36 B undefined110.56 B undefined80.52 B undefined
2021309.28 B undefined98.49 B undefined75.43 B undefined
2020292.42 B undefined77.45 B undefined59.7 B undefined
2019288.63 B undefined63.31 B undefined51.54 B undefined
2018261.84 B undefined57.95 B undefined50.28 B undefined
2017244.8 B undefined76.1 B undefined55.79 B undefined
2016160.28 B undefined30.39 B undefined24.98 B undefined
2015135.78 B undefined14.79 B undefined12.98 B undefined
2014143.25 B undefined26.42 B undefined20.35 B undefined
2013145.39 B undefined31.92 B undefined24.12 B undefined
2012145.78 B undefined37.9 B undefined24.36 B undefined
2011135.26 B undefined35.2 B undefined24.22 B undefined
2010135.99 B undefined39.84 B undefined27.88 B undefined
2009136.56 B undefined43.47 B undefined23.77 B undefined
2008145.9 B undefined52.29 B undefined35.05 B undefined
2007141.71 B undefined52.84 B undefined35.27 B undefined
2006148.67 B undefined56.94 B undefined36.09 B undefined
2005145.3 B undefined60.05 B undefined39.24 B undefined

Ono Pharmaceutical Co stock margins

The Ono Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ono Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ono Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ono Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Ono Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ono Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ono Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ono Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ono Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ono Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ono Pharmaceutical Co Margin History

Ono Pharmaceutical Co Gross marginOno Pharmaceutical Co Profit marginOno Pharmaceutical Co EBIT marginOno Pharmaceutical Co Profit margin
2027e74.71 %23.44 %17.68 %
2026e74.71 %21.83 %17.2 %
2025e74.71 %21.45 %17.38 %
202474.71 %31.84 %25.46 %
202375.39 %33.49 %25.21 %
202274.12 %30.6 %22.28 %
202172.33 %31.84 %24.39 %
202072.96 %26.49 %20.42 %
201970.96 %21.93 %17.86 %
201875.03 %22.13 %19.2 %
201773.23 %31.09 %22.79 %
201674.09 %18.96 %15.58 %
201574.12 %10.9 %9.56 %
201477.14 %18.45 %14.21 %
201376.63 %21.95 %16.59 %
201280.12 %26 %16.71 %
201181.69 %26.03 %17.91 %
201084.68 %29.3 %20.5 %
200984.39 %31.83 %17.4 %
200885.7 %35.84 %24.02 %
200785.12 %37.29 %24.89 %
200685.33 %38.3 %24.27 %
200585.54 %41.32 %27 %

Ono Pharmaceutical Co Aktienanalyse

What does Ono Pharmaceutical Co do?

Ono Pharmaceutical Co Ltd is a Japanese company specialized in the development and marketing of innovative medications. It has a long history, being founded in 1717. Originally, it was a Chinese medicine business, but since its establishment in 1924, Ono Pharmaceutical has focused on the development of modern medications. The company's business model is based on research and development of medications. Ono Pharmaceutical has several branches in different countries and works closely with research institutions and universities to develop groundbreaking medications. The company is committed to providing innovative therapies to patients worldwide. Ono Pharmaceutical specializes in several areas, including oncology, immunology, neurology, and diabetes. In oncology, the company has launched several medications, including Opdivo and Sprycel, used for the treatment of various forms of cancer. Opdivo is an immunooncological medication that shows great promise and is used worldwide. In immunology, Ono Pharmaceutical has developed a range of medications, including Nivolumab, used for the treatment of various autoimmune diseases such as rheumatoid arthritis. Ono Pharmaceutical has also developed medications for influenza and other types of infections. In the field of neurology, the company has developed medications used for pain treatment, including the compound Fauldopamine. Despite the discovery of Fauldopamine, which is considered suitable for pain treatment, no final decision has been made regarding the application of this medication. In diabetes research, Ono Pharmaceutical has developed various medications used for the treatment of diabetes, including Alogliptin and Canagliflozin. These medications help diabetics better control their blood sugar levels and alleviate the symptoms of this disease. Ono Pharmaceutical has also launched numerous products used in different areas, such as Desitin, a cream for the treatment of skin disorders, or Minon, a skincare line. The company places great importance on collaboration and innovation to provide highly effective medications to patients. Ono Pharmaceutical is committed to expanding its presence in the global market and developing further innovative therapies to improve people's lives. Ono Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Ono Pharmaceutical Co's EBIT

Ono Pharmaceutical Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Ono Pharmaceutical Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Ono Pharmaceutical Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Ono Pharmaceutical Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Ono Pharmaceutical Co stock

How much did Ono Pharmaceutical Co achieve in EBIT for the current year?

In the current year, Ono Pharmaceutical Co has achieved an EBIT of 160.05 B JPY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Ono Pharmaceutical Co.

How has the EBIT of Ono Pharmaceutical Co developed in recent years?

The EBIT of Ono Pharmaceutical Co has increased by 6.87% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Ono Pharmaceutical Co?

The EBIT of Ono Pharmaceutical Co is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Ono Pharmaceutical Co pay?

Over the past 12 months, Ono Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 3.6 %. For the coming 12 months, Ono Pharmaceutical Co is expected to pay a dividend of 86.14 JPY.

What is the dividend yield of Ono Pharmaceutical Co?

The current dividend yield of Ono Pharmaceutical Co is 3.6 %.

When does Ono Pharmaceutical Co pay dividends?

Ono Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Ono Pharmaceutical Co?

Ono Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Ono Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 86.14 JPY are expected. This corresponds to a dividend yield of 3.88 %.

In which sector is Ono Pharmaceutical Co located?

Ono Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ono Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ono Pharmaceutical Co from 12/1/2024 amounting to 40 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Ono Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Ono Pharmaceutical Co in the year 2023?

In the year 2023, Ono Pharmaceutical Co distributed 77 JPY as dividends.

In which currency does Ono Pharmaceutical Co pay out the dividend?

The dividends of Ono Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ono Pharmaceutical Co

Our stock analysis for Ono Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ono Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.